Xing Zhang

机构：The University of Texas MD Anderson Cancer Center, Sun Yat-sen University, Wuhan Puai Hospital, Sun Yat-sen University Cancer Center, RWTH Aachen University · ORCID：0000-0003-2665-6940

发表论文 249 篇 · 总被引 3491 次 · h-index 33

代表论文

• A phase 2 study of novel MDM2 inhibitor alrizomadlin (APG-115) with or without toripalimab in patients (pts) with advanced adenoid cystic carcinoma (ACC) or other solid tumors. (2025 · Journal of Clinical Oncology · 被引 5)
• Adrenomedullin Inhibits the Efficacy of Combined Immunotherapy and Targeted Therapy in Biliary Tract Cancer by Disrupting Endothelial Cell Functions (2025 · Journal of Cellular and Molecular Medicine · 被引 5)
• Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC (2025 · iScience · 被引 3)
• Sulforaphane regulates hepatic autophagy and apoptosis by modulating Kupffer cells’ polarization via Nrf2/HO-1 pathway in the murine hemorrhagic shock/resuscitation model (2025 · European Journal of Trauma and Emergency Surgery · 被引 3)
• Methods for Characterization and Optimization of Peptide Therapeutics: Bioanalysis and Biotransformation (2025 · 被引 2)
• Tracing the history of clinical practice of liquid biopsy: a bibliometric analysis (2025 · Frontiers in Immunology · 被引 2)